T. Rowe Price Investment Management, Inc. filed a Schedule 13G with the SEC on November 16, 2026, disclosing a beneficial ownership position in Relay Therapeutics, Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 17,868,157 shares of Relay Therapeutics common stock.
- Percent of class: The reported position represents 8.2% of the outstanding class of common stock.
- Sole voting power: The filing disclosed sole voting power over 17,031,683 shares.
- Sole dispositive power: The filer reported sole dispositive power over all 17,868,157 shares.
- Shared voting and dispositive power: Both shared voting power and shared dispositive power were reported as 0.
- Triggering event date: The date of the event requiring this filing was September 30, 2026.
- Filer classification: T. Rowe Price Investment Management, Inc. is identified as an investment adviser, organized in Maryland, with its principal office at 1307 Point Street, Baltimore, MD 21231.
T. Rowe Price Investment Management Discloses 8.2% Position in Relay Therapeutics Common Stock
According to the Schedule 13G filed on November 16, 2026, T. Rowe Price Investment Management, Inc. held an aggregate beneficial ownership of 17,868,157 shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) common stock (CUSIP 75943R102) as of September 30, 2026, representing 8.2% of the class. The filing was submitted by Vice President Ellen York on behalf of the firm.
The filing disclosed that T. Rowe Price Investment Management held sole voting power over 17,031,683 shares and sole dispositive power over the full 17,868,157 shares. No shares were subject to shared voting or shared dispositive power, according to the filing. The filer is classified as an investment adviser (type "IA") under the reporting rules, organized under the laws of Maryland.
In its certification, the company stated that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing also noted that T. Rowe Price Investment Management "expressly denied" that the filing constitutes an admission of beneficial ownership of the securities referred to. Relay Therapeutics is headquartered at 60 Hampshire Street, Cambridge, MA 02139, according to the filing.
What Was Disclosed
T. Rowe Price Investment Management, Inc. filed a Schedule 13G reporting beneficial ownership of 17,868,157 shares, or 8.2%, of Relay Therapeutics, Inc. common stock as of September 30, 2026, with sole voting power over 17,031,683 shares and sole dispositive power over all reported shares.




Please wait processing your request...